Controversies in Stem Cell Transplantation and Cellular Therapies 8th Congress 2023

Controversies in Stem Cell Transplantation and Cellular Therapies 8th Congress 2023

Format: 5 videos + 1 pdf, size: 52.7 GB

Course Audience: oncologist, hematologist

Overview:

The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) was held on 19-21 October, 2023, in Berlin, Germany, and virtually. This meeting was an opportunity for experts to come together and debate key topics in the field of transplantation and cellular therapies for hematological malignancies.

The congress addressed major questions regarding indication, timing, and patients’ selection for stem cell transplantation. It also discussed alternative non-transplant treatment options, especially regarding the inherent risk of treatment-related complications of stem cell transplantation such as graft-versus-host disease and infectious complications.

Moreover, the type of conditioning pre-transplantation regiments and specifically traditional myeloablative versus non-myeloablative, reduced intensity, and lately reduced toxicity, type of pre-transplantation protocols aiming in keeping the anti-tumoral effect of the transplant while reducing transplant-related organ toxicities was also debatable.

The optimal graft source, cell subset composition, and cell dose are yet to be determined. Valid alternatives include human leukocyte antigen-matched unrelated bone marrow versus mobilized peripheral blood, granulocyte-colony-stimulating factor versus CXCR4 blockade-based mobilization autologous stem cells and human umbilical cord blood versus haploidentical donor-mobilized stem cells.

The role of mesenchymal and T regulatory cells for tolerance induction on one hand and cytotoxic T cells and natural killer cells for anti-tumor effect on the other, in the future engineered grafts, is an attractive topic, as well.

Finally, transplantation should be considered as only one step in the anti-malignant therapy aiming in conquering the disease, and as such should be combined with pre- and post-transplant targeted therapy aiming to achieve minimal tumor burden pre-transplantation and to prevent tumor progression and relapse post-transplantation.

Main Topic

• Acute leukemia

• Bi-specific antibodies

• CMV infection

• CAR T-cell therapy and cellular therapy

• Cord blood transplantation

• Donor lymphocyte infusion

• Drug conjugated antibodies

• Genome editing and gene therapy

• GvHD prevention and treatment

• Haploidentical stem cell transplantation

• Hodgkin and Non-Hodgkin lymphoma

• Mesenchymal stem cell

• Multiple myeloma

• Myeloproliferative neoplasm

• Myelodysplastic syndrome

• NK Cell therapy

• Pediatric indications for transplantation

• Relapse prevention

• Toxicity post transplantation (VOD, TMA, etc.)

• Transplant for severe aplastic anemia and hemoglobinopathies

• Virus specific T Cell therapy

*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below

October 19 Hall B (Video MP4 Format)

October 20 Hall A (Video MP4 Format)

October 20 Hall B (Video MP4 Format)

October 21 Hall A (Video MP4 Format)

October 21 Hall B (Video MP4 Format)

Scientific Program – COSTEM 2023 (PDF Format)

*Detail: